Question Bank › Candid stewardship of one big open question

Candid stewardship of one big open question

Candid stewardship of one big open question: management engages seriously with a consequential unresolved outcome

Calls Tested
332
Answered YES
81
Hit Rate
24.4%
rare by design

Ultralife Corporation (ULBI) — this company's answers

NO on the Q3 2016 call 2016-10-29 C+
The model's full reasoning — Q3 2016 call → NO我们根据提供的财报电话会议记录,判断管理层是否识别并认真讨论了一个尚未解决的重要运营成果。需要寻找一个具体的、正在进行的、结果未知的、有实质细节和坦诚讨论的举措。 在记录中,管理层提到了多个举措,如Viper项目、Accutronics整合、医疗市场增长、新客户开发等。其中,Viper项目有后续订单,但已交付初始订单,后续订单已收到,似乎结果已部分确定。Accutronics整合已实现盈利,但仍在发展。更关键的是,管理层提到“我们仍然积极寻找下一个收购”,并任命专人负责M&A,但这是计划中的,不是已在进行的具体举措。 另一个候选是“医疗市场”的多元化,但这是整体战略,不是单一具体举措。管理层在回答分析师问题时,对Viper后续订单、Accutronics盈利、医疗订单等提供了具体数字和细节,但这些都是已发生或已确定的事情。 需要找到一个“结果未知”的正在进行的举措。例如,管理层提到“我们正在开发下一代3伏锂金属产品线”等,但这是产品开发,尚未有结果。但管理层没有详细讨论其进展和风险。 更符合的是“Viper项目”的后续订单,但已收到订单,结果已部分确定。或者“Accutronics”的整合,但已实现盈利,结果已确定。 或许“寻找下一个收购”是计划,不是已在进行。 再仔细看,管理层在回答分析师关于Viper后续订单时,说“我们不知道最终预算如何”,承认不确定性,但这是关于未来订单,不是当前正在进行的举措。 另一个是“医疗市场”的客户开发,如提到的“全球医疗设备制造商关系”,有7个新开发活动,但结果未知。管理层提供了具体细节,如“13次客户拜访”等,但这是日常活动。 我认为没有明确的一个“具体、正在进行的、结果未知的”举措被管理层以坦诚和具体的方式讨论。管理层更多是报告已完成的成果和未来计划。 因此,答案应为NO。

← Back to the full ULBI analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management identify and seriously engage with ONE CONSEQUENTIAL OPERATIONAL OUTCOME THAT IS STILL UNRESOLVED — a specific, identifiable thing already in motion at the company (such as a ramp, launch, expansion, qualification, negotiation, integration, or scale-up) whose result is not yet known — AND does management discuss it with visible candor and operational specificity: explaining what is going well and what is not yet proven, what the company is doing about it right now, and what would make it succeed or fall short — rather than either hyping it as a sure thing or hiding it in vague language? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent posture: there is a specific undertaking already underway whose outcome would meaningfully change the company's trajectory if it goes well, management treats it as genuinely open rather than assured, and management demonstrates command of its moving parts — describing current progress with concrete operational detail, acknowledging the parts that remain unproven or difficult, and explaining the actions being taken now to push it toward success. The undertaking may take whatever form fits the industry, and the candor may show up in prepared remarks or in direct, substantive answers to analyst probing. Answer NO if the call contains no identifiable consequential undertaking whose outcome is still open — for example a steady business reporting routine results. NO if management presents its key initiative as a guaranteed success with no acknowledged uncertainty or unproven elements. NO if the discussion of the undertaking is vague, promotional, or evasive — big-market talk, mission language, or deflected questions — without operational specifics about current progress and remaining risk. NO if the unresolved matter is chiefly a threat to survival (funding, going concern, covenant relief) rather than an undertaking that could make the company meaningfully bigger. NO if the undertaking is only planned or contemplated rather than already in motion. NO if the candid framing appears only in an analyst's question that management does not itself engage with substantively. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
MCD McDonald's Corporation Q2 2024 2024-07-29 D
MMLP Martin Midstream Partners L.P. Q2 2024 2024-07-18 B
HCKT The Hackett Group, Inc. Q1 2024 2024-05-08 C
CTRA Coterra Energy Inc. Q1 2024 2024-05-03 A
SNV Synovus Financial Corp. Q1 2024 2024-04-18 B
CLGN CollPlant Biotechnologies Ltd. Q4 2023 2024-04-04 F
ASM Avino Silver & Gold Mines Ltd. Q4 2023 2024-03-21 C+
LEGH Legacy Housing Corporation Q4 2023 2024-03-18 C
SANG Sangoma Technologies Corporation Q2 2024 2024-02-08 D
DXCM DexCom, Inc. Q4 2023 2024-02-08 B+
GPRE Green Plains Inc. Q4 2023 2024-02-07 F
BRBR BellRing Brands, Inc. Q4 2023 2023-11-21 B+
SCPH scPharmaceuticals Inc. Q3 2023 2023-11-08 B
QTRX Quanterix Corporation Q3 2023 2023-11-07 B
ALL The Allstate Corporation Q3 2023 2023-11-02 C+
GOLD Barrick Gold Corporation Q3 2023 2023-11-02 C
CMG Chipotle Mexican Grill, Inc. Q3 2023 2023-10-27 B+
PTN Palatin Technologies, Inc. Q4 2023 2023-09-29 D
KMDA Kamada Ltd. Q2 2023 2023-08-16 B+
AKYA Akoya Biosciences, Inc. Q2 2023 2023-08-07 C+
CTO CTO Realty Growth, Inc. Q2 2023 2023-07-28 B
GGR Gogoro Inc. Q1 2023 2023-05-11 D
SLDP Solid Power, Inc. Q1 2023 2023-05-08 C+
CARS Cars.com Inc. Q1 2023 2023-05-06 B
KE Kimball Electronics, Inc. Q3 2023 2023-05-06 C+
TACT TransAct Technologies Incorporated Q4 2022 2023-03-08 A
ORGO Organogenesis Holdings Inc. Q4 2022 2023-03-01 C
TWLO Twilio Inc. Q4 2022 2023-02-15 D
PI Impinj, Inc. Q4 2022 2023-02-08 B+
CEIX CONSOL Energy Inc. Q4 2022 2023-02-07 B
REGN Regeneron Pharmaceuticals, Inc. Q4 2022 2023-02-03 C
CUE Cue Biopharma, Inc. Q3 2022 2022-11-14 D
HBB Hamilton Beach Brands Holding Company Q3 2022 2022-11-05 C
CHE Chemed Corporation Q3 2022 2022-11-01 B+
ASTS AST SpaceMobile, Inc. Q2 2022 2022-08-15 D
CRL Charles River Laboratories International Q2 2022 2022-08-03 C
SYM Symbotic Inc. Q3 2022 2022-08-01 B+
JBHT J.B. Hunt Transport Services, Inc. Q2 2022 2022-07-19 C+
SE Sea Limited Q1 2022 2022-05-17 F
BFIN BankFinancial Corporation Q1 2022 2022-05-06 A
SOPH SOPHiA GENETICS SA Q4 2021 2022-03-15 C
HROW Harrow Health, Inc. Q4 2021 2022-03-10 C
CDXC ChromaDex Corporation Q4 2021 2022-03-09 C+
VNDA Vanda Pharmaceuticals Inc. Q4 2021 2022-02-23 F
FLUX Flux Power Holdings, Inc. Q2 2022 2022-02-10 D
OOMA Ooma, Inc. Q3 2022 2021-12-02 B+
MOMO Hello Group Inc. Q3 2021 2021-11-30 D
HNRG Hallador Energy Company Q3 2021 2021-11-09 C+
AKBA Akebia Therapeutics, Inc. Q3 2021 2021-11-09 C+
ALHC Alignment Healthcare, Inc. Q3 2021 2021-11-06 B+
EGY VAALCO Energy, Inc. Q2 2021 2021-08-12 B
OWL Blue Owl Capital Inc. Q2 2021 2021-08-10 B+
LOPE Grand Canyon Education, Inc. Q2 2021 2021-08-08 C
AX Axos Financial, Inc. Q4 2021 2021-07-29 C+
ESRT Empire State Realty Trust, Inc. Q2 2021 2021-07-29 C+
LOB Live Oak Bancshares, Inc. Q3 2018 2018-10-25 C+
KOP Koppers Holdings Inc. Q2 2018 2018-08-12 C+
SRDX Surmodics, Inc. Q3 2018 2018-08-06 A
YUM Yum! Brands, Inc. Q2 2018 2018-08-02 C
PCRX Pacira BioSciences, Inc. Q4 2017 2018-02-28 C
UAA Under Armour, Inc. Q3 2017 2017-10-31 F
FLEX Flex Ltd. Q1 2018 2017-07-28 F
DHX DHI Group, Inc. Q2 2017 2017-07-28 D
PLAB Photronics, Inc. Q2 2017 2017-05-17 C+
TPB Turning Point Brands, Inc. Q1 2017 2017-05-11 B
ANIP ANI Pharmaceuticals, Inc. Q4 2016 2017-03-02 B+
MRIN Marin Software Incorporated Q4 2016 2017-02-28 D
ATO Atmos Energy Corporation Q1 2017 2017-02-08 A
FIBK First Interstate BancSystem, Inc. Q4 2016 2017-01-27 B+
SUPN Supernus Pharmaceuticals, Inc. Q3 2016 2016-11-18 D
WYY WidePoint Corporation Q3 2016 2016-11-09 D
SOHO Sotherly Hotels Inc. Q3 2016 2016-11-08 D
FATE Fate Therapeutics, Inc. Q3 2016 2016-11-07 C
TGI Triumph Group, Inc. Q2 2017 2016-11-03 C+
NTCT NetScout Systems, Inc. Q2 2017 2016-10-27 D
ARAY Accuray Incorporated Q4 2016 2016-08-17 B
CHDN Churchill Downs Incorporated Q2 2016 2016-08-04 C+
CRIS Curis, Inc. Q1 2016 2016-05-09 C
GOGO Gogo Inc. Q1 2016 2016-05-06 C+
ESE ESCO Technologies Inc. Q2 2016 2016-05-03 A
SPR Spirit AeroSystems Holdings, Inc. Q1 2016 2016-04-29 D

How the model reasoned

TACT · Q4 2022 → YESThe question is: Does management identify and seriously engage with ONE CONSEQUENTIAL OPERATIONAL OUTCOME THAT IS STILL UNRESOLVED... YES The transcript shows management seriously engaging with the large QSR rollout as a specific, already-in-motion undertaking whose outcome remains open. Bart describes it as an ongoing testing and implementation process that has taken over two years, with the company expecting it to begin rolling out in the second half of 2023 (mid-to end of Q3 through Q4) if testing succeeds. He notes recent new orders coming in during Q1, acknowledges the process has had “starts and stops,” and frames success around whether testing goes right and whether the pipeline continues to convert. Steve adds that the rollout will drive significant FST growth in 2024 2023. This is treated as genuinely uncertain rather than assured, with concrete operational details on current progress (new orders, testing), remaining risks (testing outcome, integration), and actions being taken (staying close to the customer, filling the pipeline).
FLUX · Q2 2022 → YESThe question is: Does management identify and seriously engage with ONE CONSEQUENTIAL OPERATIONAL OUTCOME THAT IS STILL UNRESOLVED... YES The transcript shows management actively engaging with the unresolved outcome of scaling production to fulfill the record $31.4 million backlog while restoring gross margins, a specific undertaking already in motion through lean manufacturing, second-shift ramp (launching this month), Mexico sourcing, design cost reductions, and aggressive supplier negotiations. They describe concrete progress (weekly orders, production throughput improvements, quality initiatives) alongside acknowledged risks (chip and component shortages, delayed price effects, inventory commitments), explain current actions (vendor metrics, alternate suppliers, ERP changes), and outline success factors (higher-margin large-pack mix, reduced overstocking).
UAA · Q3 2017 → YESThe question is: Does management identify and seriously engage with ONE CONSEQUENTIAL OPERATIONAL OUTCOME THAT IS STILL UNRESOLVED — a specific, identifiable thing already in motion... whose result is...YES The transcript shows management identifying the ERP system implementation (launched July 1) as a specific, already-in-motion operational outcome whose result remains unresolved. They detail concrete progress (system now stable, service levels improving) and current actions (ongoing change management with vendors and workforce, fine-tuning through Q4 into 2018), while openly noting residual impacts on shipments and productivity that will not fully resolve until later in the year. This is framed as a genuine risk to Q4 and full-year results rather than a guaranteed success, with visible operational specificity on what is working and what remains unproven.

More from the question bank

The company's own money is now going somewheOutgrowing the shellEveryday buyers, repeat needDemand off the charts · scarcity_amplificatiManagement is re-underwriting a specific assManagement is playing referee between competAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.